Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ImageneBio, Inc.IKNA · Entity 7139 | Chief Medical Officer | January 03, 2023 | January 05, 2023 |
| MERRIMACK PHARMACEUTICALS INCMACK · Entity 95770 | Chief Medical Officer | December 11, 2018 | December 13, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ImageneBio, Inc.
Report date January 03, 2023 · Filed January 05, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.62 · Expires 2033-01-03 | Direct | 105,000 |
Reported balance
After 2023-01-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-01-03 · Grant · Acquired 105,000 · Balance 105,000 F1: 25% of the shares subject to this option shall vest and become exercisable on January 1, 2024, with the remainder vesting in 36 substantially equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to this option shall vest and become exercisable on January 1, 2024, with the remainder vesting in 36 substantially equal monthly installments thereafter.
MERRIMACK PHARMACEUTICALS INC
Report date December 11, 2018 · Filed December 13, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.15 · Expires 2028-12-10 | Direct | 45,000 |
Reported balance
After 2018-12-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-12-11 · Grant · Acquired 45,000 · Balance 45,000 F1: This option vests as to 1/12th of the total number of shares granted on 3/11/19 and an additional 1/12th of the total number of shares granted at the end of each successive three month period thereafter until 12/11/21. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests as to 1/12th of the total number of shares granted on 3/11/19 and an additional 1/12th of the total number of shares granted at the end of each successive three month period thereafter until 12/11/21.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 03, 2023 Filed Jan 5, 2023 16:15 UTC | ImageneBio, Inc. IKNA · Entity 7139 | GrantStock Option (Right to Buy) · Derivative | 105,000 | $0.00 Strike: $2.62 | $0.00 |
DisclosureSEC source: 0000899243-23-000989 · doc4.xml · derivative · entry 1 Santillana Sergio L. · CIK 0001708767 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 105,000 shares Expires 2033-01-03 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on January 1, 2024, with the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 18:12 UTC | ImageneBio, Inc. IKNA · Entity 7139 | GrantStock Option (Right to Buy) · Derivative | 70,400 | $0.00 Strike: $11.45 | $0.00 |
DisclosureSEC source: 0000899243-22-004886 · doc4.xml · derivative · entry 1 Santillana Sergio L. · CIK 0001708767 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,400 Underlying: Common Stock · 70,400 shares Expires 2032-02-02 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on January 1, 2023, with the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| December 11, 2018 Filed Dec 13, 2018 16:20 UTC | MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770 | GrantStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $4.15 | $0.00 |
DisclosureSEC source: 0001209191-18-062440 · doc4.xml · derivative · entry 1 Santillana Sergio L. · CIK 0001708767 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2028-12-10 F1 · derivative.exercise_date: This option vests as to 1/12th of the total number of shares granted on 3/11/19 and an additional 1/12th of the total number of shares granted at the end of each successive three month period thereafter until 12/11/21. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 16:13 UTC | MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770 | GrantStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $10.74 | $0.00 |
DisclosureSEC source: 0001209191-18-010821 · doc4.xml · derivative · entry 1 Santillana Sergio L. · CIK 0001708767 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2028-02-14 F1 · derivative.exercise_date: This option vests as to 1/12th of the total number of shares granted on 5/15/18 and an additional 1/12th of the total number of shares granted at the end of each successive three month period thereafter until 2/15/21. Read SEC document |
| June 13, 2017 Filed Jun 15, 2017 16:24 UTC | MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770 | GrantStock Option (right to buy) · Derivative | 450,000 | $0.00 Strike: $1.35 | $0.00 |
DisclosureSEC source: 0001209191-17-040140 · doc4.xml · derivative · entry 1 Santillana Sergio L. · CIK 0001708767 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 450,000 shares Expires 2027-06-12 F1 · derivative.exercise_date: This option vests as to 1/6th of the total number of shares granted on 12/12/17 and an additional 1/12th of the total number of shares granted at the end of each successive three month period thereafter until 6/12/20. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.